

## Corrigendum


# Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms

B Liu, JK Wen, BH Li, XM Fang, JJ Wang, YP Zhang, CJ Shi, DQ Zhang and M Han

*Cell Death and Disease* (2011) 2, e206; doi:10.1038/cddis.2011.92; published online 1 September 2011

**Correction to:** *Cell Death and Disease* (2011) 2, e185; The authors would like to apologize for this error.  
 Published online 28 July 2011; doi:10.1038/cddis.2011.64

Since the publication of the article, the Authors and Editors have determined that Figure 3a was incorrect. The figure below is the correct version.



**Figure 3** Effects of the combination of celecoxib and ABL on COX-2 expression and activity in MDA-MD-231 cells. **(a)** MDA-MD-231 cells were treated with celecoxib, ABL or their combination for 24 h (left) or 48 h (right). COX-2 mRNA and protein expression was examined using RT-PCR (left) and western blot analysis (right). Quantification of COX-2 mRNA and protein expression normalized to actin levels, were provided at the bottom. **(b)** MDA-MB-231 cells were treated with the combination for 48 h, and PGE<sub>2</sub> levels in the culture medium were measured using ELISA. Results were expressed as mean ± S.E.M. from at least three independent experiments